By opposing making clinical trial data public, Pharma is once again swimming against the current
CMS recognized that the rules in place for CME provide for separation from supporter influence
Just like the NSA can monitor national security, FDA market-watchers can track what pharma marketers are doing.
While there are successes in the battle for better adherence/compliance, we’re losing the war
Appendages of the HHS secretary’s apron strings, FDA commissioners must toe the “party line”
People in the industry must be worried about the type of care doctors are now giving
While we all like the sun, life under the final rules for the “Sunshine Act” provisions of the Affordable Care Act is going to be complicated and treacherous for drug companies and their agencies.
FDA has never won a First Amendment case, and its string of losses led it to bring this one under false colors
The image of pharma as corrupt is not a problem of perception. It’s one of fact.
Major provisions in the FDA Safety and Innovation Act could make the approval process more transparent
MM+M Transform: The Patient, Provider and Payer Engagement Matrix provides the most in-depth look at the marketing and technology trends likely to influence the industry’s growth over the next year.
Get the most out of
Register for free and enjoy unlimited access to: